{"id":"kps-0373-low-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Polyuria"},{"rate":null,"effect":"Polydipsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the kidney, leading to increased urinary glucose excretion and lower blood glucose levels. This mechanism is independent of insulin secretion and provides cardiovascular and renal protective benefits beyond glycemic control.","oneSentence":"KPS-0373 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:11.004Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01970098","phase":"PHASE3","title":"A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2013-10-09","conditions":"Spinocerebellar Degeneration","enrollment":374},{"nctId":"NCT01970137","phase":"PHASE3","title":"A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":""},{"nctId":"NCT01970111","phase":"PHASE3","title":"An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":""},{"nctId":"NCT01970124","phase":"PHASE3","title":"A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":130736,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KPS-0373, Low dose","genericName":"KPS-0373, Low dose","companyName":"Kissei Pharmaceutical Co., Ltd.","companyId":"kissei-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KPS-0373 is a small molecule thyrotropin-releasing hormone receptor agonist, classified as an agonist. It has been studied in a completed clinical trial (NCT01970124) for the treatment of spinocerebellar degeneration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}